Jyong Biotech Ltd. Ordinary Shares (MENS) Stock

Jyong Biotech Ltd. Ordinary Shares (MENS) is a Healthcare stock trading at $1.55 (as of 2026-06-18), with a market capitalization of $167.26M and a trailing P/E of -26.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages

Valuation — source: SEC EDGAR (first-party)
Price	$1.55
Market Cap	$167.26M
P/E Ratio	-26.0
EV / EBITDA	-53.8
Price / Book	-4.76
Price / Sales	194.43
DCF Value (model)	$-0.90
DCF Upside vs Price	-158.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$610000.00
Net Margin	-765.7%
Return on Equity	18.8%
Debt / Equity	-0.70
Current Ratio	0.45
Revenue Growth (YoY)	8614.3%
EPS Growth (YoY)	50.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.49 (distress)

Valuation vs Sector & Industry
Stock P/E	-26.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-224.5%
vs Industry	-252.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($556334.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Fu-Feng Kuo
Employees	31
Country	TW
IPO Date	2025-06-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.